Arthritis J Anastasi

Cure Arthritis Naturally

Beat Arthritis Naturally

Get Instant Access

Ahmad, I., Al-Katib, A. M., et al. (2000). Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report. Clin Cancer Res: Official J Am Assoc Cancer Res 6(4), 1328-1332.

Arner, E. S. (1996). On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk Lymphoma 21(3-4), 225-231.

Beck, F. W., Al-Katib, A. M., et al. (2000). Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. Int J Mol Med 5(4), 341-347.

Beck, F. W. J., Eilender, D. S., et al. (2004). Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia. Int J Mol Med 14(1), 113-119.

Beutler, E. (1993). Use of 2-halo adenosine derivatives as therapeutic agents against chronic myelogenous leukemia. PCT International Application Wo, Scripps Research Institute, USA, 35 pp.

Beutler, E., Sipe, J. C., et al. (1996). The treatment of chronic progressive multiple sclerosis with cladribine. Proc Nat Acad Sci USA 93(4), 1716-1720.

Beutler, E., Carson, D., et al. (1997a). 2-Chlorodeoxyadenosine in nonmalignant disorders. Basic Clin Oncol 12(Nucleoside Analogs in Cancer Therapy), 359-382.

Beutler, E., McMillan, R., et al. (1997b). Development of 2-chlorodeoxyadenosine (2-CdA) as a chemotherapeutic and immunosuppressive drug. Basic Clin Oncol 12(Nucleoside Analogs in Cancer Therapy), 159-173.

Blank, W. A., Elder, K. J., et al. (1992). Synthesis of 2-chloro-2'-deoxyadenosine by washed cells of E. coli. Biotechnol Lett 14(8), 669-672.

Bos, J. D., Meinardi, M. M., et al. (1989). Use of cyclosporin in psoriasis. Lancet 2(8678-8679), 1500-1502.

Bzowska, A., and Kazimierczuk, Z. (1995). 2-Chloro-2'-deoxyadenosine (cladribine) and its analogs are good substrates and potent selective inhibitors of Escherichia coli purine-nucleoside phosphorylase. Eur J Biochem 233(3), 886-890.

Canfield, V. A., Vose, J., et al. (1997). 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Leuk Lymphoma 24(3-4), 335-339.

Carrera, C. J., Terai, C., et al. (1990). Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. Journal Clin Invest 86(5), 1480-1408.

Carson, D. A., Kaye, J., et al. (1977). Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Nat Acad Sci USA 74(12), 5677-5681.

Carson, D. A., Wasson, D. B., et al. (1980). Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proceedings of the National Academy of Sci USA 77(11), 6865-6869.

Carson, D. A., Wasson, D. B., et al. (1983). Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62(4), 737-743.

Carson, D. A., Wasson, D. B., et al. (1984). Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Nat Acad Sci USA 81(7), 2232-2236.

Carson, D. A., Wasson, D. B., et al. (1992). Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc Nat Acad Sci USA 89(7), 2970-2974.

Christensen, L. F., Broom, A. D., et al. (1972). Synthesis and biological activity of selected 2,6-disub-stituted(2-deoxy-a- and -b-D-erythro-pentofuranosyl)purines. J Med Chem 15(7), 735-739.

Chunduru, S. K., Appleman, J. R., et al. (1993). Activity of human DNA polymerases alpha and beta with 2-chloro-2'-deoxyadenosine 5'-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys 302(1), 19-30.

Cohen, A., Hirschhorn, R., et al. (1978). Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Nat Acad Sci USA 75(1), 472-476.

Crawford, C. R., Ng, C. Y., et al. (1990). Isolation and characterization of an L1210 cell line retaining the sodium-dependent carrier cif as its sole nucleoside transport activity. J Biol Chem 265(23), 13730-13734.

Dann, E. J., Anastasi, J., et al. (1998). High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol: Official J Am Soc Clin Oncol 16(4), 1498-1504.

Dimopoulos, M. A., Kantarjian, H., et al. (1993). Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Internal Med 118(3), 195-198.

Dimopoulos, M. A., Kantarjian, H. M., et al. (1992). 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 80(6), 1626.

Dimopoulos, M. A., Theodorakis, M., et al. (1997). Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leuk Lymphoma 25(1-2), 187-189.

Duchini, A., Younossi, Z. M., et al. (2000). An open-label pilot trial of cladribine (2-chlorodeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 31(4), 292-296.

Dumontet, C., Fabianowska-Majewska, K., et al. (1999). Common resistance mechanisms to deoxynucleo-side analogs in variants of the human erythroleukemic line K562. Br J Haematol 106(1), 78-85.

Eibschutz, B., Baird, S. M., et al. (1995). Oral 2-chlorodeoxyadenosine in psoriatic arthritis: A preliminary report. Arthritis Rheum 38(11), 1604-1609.

Escoda, L., Lopez-Guillermo, A., et al. (1990). Treatment of various lymphoproliferative syndromes with deoxycoformycin: Results in 6 patients. Sangre 35(6), 421-424.

Faderl, S., Gandhi, V., et al. (2005). The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer (New York, NY, United States) 103(10), 1985-1995.

Foon, K. A., Rai, K. R., et al. (1990). Chronic lymphocytic leukemia: New insights into biology and therapy. Ann Intern Med 113(7), 525-539.

Fridrik, M. A., Jager, G., et al. (1997). First-line treatment of Waldenstrom's disease with cladribine. Arbeitsgemeinschaft Medikamentose Tumortherapie. Ann Hematol 74(1), 7-10.

Genini, D., Adachi, S., et al. (2000). Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96(10), 3537-3543.

Gerszberg, S., and Alonso, D. (2000). Method for the production of of antitumor 2-chloro-2'-deoxyade-nosine (cladribine) and its 3,5-di-o-p-toluoyl derivative. PCT International Application Wo, Sterrenbeld Biotechnologie North America, Inc., USA, 22 pp.

Giblett, E. R., Anderson, J. E., et al. (1972). Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2(7786), 1067-1069.

Goodman, G. R., Beutler, E., et al. (2003). Cladribine in the treatment of hairy-cell leukaemia. Best Practice Res Clin Haematol 16(1), 101-116.

Gordon, M. S., Young, M. L., et al. (2000). Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res 24(10), 871-875.

Graziadei, I., Kelly, T., et al. (1998). Antitumor effect of the nucleoside analogs 2-chlorodeoxyade-nosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells. J Hepatol 28(3), 504509.

Griffig, J., Koob, R., et al. (1989). Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 49(24 Pt 1), 6923-6928.

Gupta, P. K., and Munk, S. A. (2004). Process for the regioselective and stereoselective preparation of 9-b-anomeric nucleoside analogs as antitumor and antiviral prodrugs. U.S. Patent Application Publication Us, Ash Stevens, Inc., USA, 10 pp.

Hafler, D. A., and Weiner, H. L. (1989). MS: A CNS and systemic autoimmune disease. Immunol Today 10(3), 104-107.

Hickish, T., Serafinowski, P., et al. (1993). 2'-Chlorodeoxyadenosine: Evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67(1), 139-143.

Hoffer, M. (1960). a-Thymidine. Chem Berichte 93, 2777-2781.

Ikehara, M., and Tada, H. (1963). New type of cyclonucleoside derived from 2-chloro-8-mercapto-9-b-D-xylofuranosyladenine. J Am Chem Society 85(15), 2344-2345.

Ikehara, M., and Tada, H. (1965). Nucleosides and nucleotides. XXIV. Purine cyclonucleosides. 1. 8,2'-Cyclonucleoside derived from 2-chloro-8-mercapto-9-b-D-xylofuranosyladenine. JAm Chem Soc 87(3), 606-610.

Janeba, Z., Francom, P., et al. (2003). Efficient syntheses of 2-chloro-2'-deoxyadenosine (Cladribine) from 2'-deoxyguanosine. J Org Chem 68(3), 989-992.

Juliusson, G., Elmhorn-Rosenborg, A., et al. (1992). Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327(15), 1056-1061.

Juliusson, G., Hoeglund, M., et al. (2003). Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. a randomized population-based phase II study. Br J Haematol 123(5), 810-818.

Karlsson, K., Stromberg, M., et al. (2002). Oral cladribine for B-cell chronic lymphocytic leukaemia: Report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients. Br J Haematol 116(3), 538-548.

Kawasaki, H., Carrera, C. J., et al. (1993). Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81(3), 597-601.

Kay, A. C., Saven, A., et al. (1992). 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol: Official J Am Soc Clin Oncol 10(3), 371-377.

Kazimierczuk, Z., and Kaminski, J. (2000). Preparation of2-chloro-2'-deoxyadenosine. Pol. Pl (Pol.), 8 pp.

Kazimierczuk, Z., Cottam, H. B., et al. (1984). Synthesis of 2'-deoxytubercidin, 2'-deoxyadenosine, and related 2'-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure. J Am Chem Soc 106(21), 6379-6382.

Keating, M. J. (1993). Chronic lymphoproliferative disorders: Chronic lymphocytic leukemia and hairy-cell leukemia. Curr Opinion Oncol 5(1), 35-41.

Keating, M. J. (1997). Future role of purine analogs in oncology. Haematol Blood Transfusion 38(Acute Leukemias VI), 380-387.

Kobayashi, K., Vogelzang, N. J., et al. (1994). A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer 74(1), 168-173.

Komatsu, H., Awano, H., et al. (2001). Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside. PCT International Application Wo, Mitsui Chemicals, Inc., Japan, 82 pp.

Langtry, H. D., and Lamb, H. M. (1998). Cladribine: A review of its use in multiple sclerosis. BioDrugs 9(5), 419-433.

Leoni, L. M., Chao, Q., et al. (1998). Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c. Proc Nat Acad Sci USA 95(16), 9567-9571.

Liliemark, J. (1997). The clinical pharmacokinetics of cladribine. Clin Pharmacokin 32(2), 120-131.

Liu, E. S., Burian, C., et al. (1998). Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinemia. Br J Haematol 103(3), 690-695.

Mikhailopulo, I. A., Zinchenko, A. I., et al. (1993). Synthesis of 2-chloro-2'-deoxyadenosine by microbiological transglycosylation. Nucleosides Nucleotides 12(3-4), 417-422.

O'Brien, S., Kantarjian, H., et al. (1996). Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Annals Oncol: Official J Eur Soc Med Oncol/ESMO 7(Suppl 6): S27-S33.

Ochs, H. D., Yount, J. E., et al. (1973). Adenosine-deaminase deficiency and severe combined immunodeficiency syndrome. Lancet 1(7816), 1393-1394.

Petersen, A. J., Brown, R. D., et al. (1996). Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur J Haematol 56(4), 213-220.

Robak, T. (2005a). The place of cladribine in the treatment of chronic lymphocytic leukemia: A 10-year experience in Poland. Ann Hematol 84(2), 63-70.

Robak, T. (2005b). Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: Facts and controversies. Drugs Aging 22(12), 983-1012.

Robak, T., Blasinska-Morawiec, M., et al. (1997). Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 58(2), 109-113.

Robak, T., Gora-Tybor, J., et al. (2001). Cladribine in combination with mitoxantrone and cyclopho-sphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 66(3), 188-194.

Robak, T., Korycka, A., et al. (2005). Purine nucleoside analogues for the treatment of hematological malignancies: Pharmacology and clinical applications. Curr Cancer Drug Targets 5(6), 421-444.

Romine, J. S., Sipe, J. C., etal. (1999). A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 111(1), 35-44.

Rummel, M. J., Chow, K. U., et al. (2002). Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. European J Cancer (Oxford, England: 1990) 38(13), 1739-1746.

Santana, V. M., Mirro, J., Jr., et al. (1992). 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol: Official J Am Soc Clin Oncol 10(3), 364-370.

Saven, A. (1996). The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Seminars Hematol 33(1 Suppl 1), 28-33.

Saven, A., Lemon, R. H., et al. (1995). 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol: Official J the Am Soc Clin Oncol 13(3), 570-574.

Saven, A., Carrera, C. J., et al. (1992). 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 80(3), 587-592.

Saven, A., Kawasaki, H., et al. (1993). 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol: Official J the Am Soc Clin Oncol 11(4), 671-678.

Saven, A., and Piro, L. D. (1994). 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 120(9), 784-791.

Saven, A., Piro, L. D., et al. (1994). Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73(12), 2953-2963.

Saven, A., Lee, T., et al. (1996). Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol: Official J Am Soc Clin Oncol 14(7), 2139-2144.

Saven, A., Lee, T., et al. (1997). Major activity of cladribine in patients with de novo B-cell pro-lymphocytic leukemia. J Clin Oncol 15(1), 37-43.

Seto, S., Carrera, C. J., et al. (1985). Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75(2), 377-383.

Simon, L. N., Bauer, R. J., et al. (1970). Calf intestine adenosine deaminase. Substrate specificity. Biochemistry 9(3), 573-577.

Tetreault, S. A., and Saven, A. (2000). Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia. Leuk Lymphoma 37(1-2), 125-130.

Ts'o, P. O. P. (Ed.) (1974). Basic Principles in Nucleic Acid Chemistry, Vol. 1.

Van Den Neste, E., Louviaux, I., et al. (2000). Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 14(6), 1136-1142.

Walker, R. T., De Clercq, E., et al. (1979). NATO Advanced Study Institutes Series, Series A: Life Sciences, Vol. 26: Nucleoside Analogs: Chemistry, Biology, and Medical Applications.

Wu, W. N., McKown, L. A., et al. (2004). Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin) in animals and humans. Xenobiotica 34(6), 591-606.

Was this article helpful?

0 0
Arthritis Relief Now

Arthritis Relief Now

When you hear the word arthritis, images of painful hands and joints comes into play. Few people fully understand arthritis and this guide is dedicated to anyone suffering with this chronic condition and wants relief now.

Get My Free Ebook


Post a comment